Investors
Building the decision layer between
primary care and cardiology
Augury Medical is a Swiss medtech company and BFH spin-off developing guideline-based clinical decision support that helps primary care physicians get cardiology patients to the right care at the right time. We are currently raising our Seed round.
The opportunity
A care gap hiding in the referral pathway
Cardiology has highly effective, guideline-recommended therapies. Too many eligible patients never reach them — not because the therapies don't exist, but because the path from primary care to the right specialist is slow, fragmented and dependent on knowledge no GP can be expected to hold in a 10-minute consult.
Up to 60%1
of qualifying CRT candidates never receive a device
Up to 80%2
of heart failure cases are diagnosed only after an emergency presentation
Up to 50%3
of qualifying severe aortic stenosis patients do not receive valve replacement
Primary care sees these patients first. We're building the tool that helps them act on that.
- Mullens W, et al. Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. Eur J Heart Fail. 2020;22(12):2349–2369. doi:10.1002/ejhf.2046
- Bottle A, et al. Routes to diagnosis of heart failure: observational study using linked data in England. Heart. 2018;104(7):600–605. doi:10.1136/heartjnl-2017-312183
- Li SX, et al. Trends in utilization of aortic valve replacement for severe aortic stenosis. J Am Coll Cardiol. 2022;79(9):864–877. doi:10.1016/j.jacc.2021.11.060
What's at stake
Every missed patient is a procedure
that came too late.
CRT devices, valve replacements, specialist monitoring: life-changing interventions that are available, guideline-supported, and too often missed because the referral gap was never closed.
Why it happens
The gap isn't in the therapies. It's in the pathway.
Primary care sees these patients first, but the tools available to them weren't built for the realities of a primary care consult.
“Fragmented guidelines. Eight minutes per consultation. A patient whose symptoms might be something serious.”
Time pressure
GPs have 8–15 minutes per consultation, with no time to manually search fragmented clinical databases.
Search-first tools
Current reference tools require specialist knowledge just to ask the right question, putting the burden on the GP.
Fragmented guidelines
Cardiovascular care spans highly specialised pathways across numerous ACC/AHA guidelines. Navigating them requires deep specialist training.
Our approach
Decision support that starts with the patient, not the search bar.
Existing reference tools assume the user already knows what to look for. Navicor works the other way round: physicians input the clinical findings they have, and Navicor matches them to the ACC/AHA guideline recommendations that apply, with the reasoning and source shown for every match.
Patient-specific, not generic
Maps each patient's clinical findings to the relevant guideline criteria, not broad population-level recommendations.
Actionable, not reference material
Every output points to a next step: which diagnostics to consider, when referral is recommended, and which treatment pathways apply.
Transparent and reviewable
The reasoning and guideline source are shown for every match, so the clinician can review the basis for each recommendation and stays in control of the decision.
Built for fast adoption
No patient-identifiable data and no integration required, removing common barriers to adopting new tools in primary care.
Our aim: the right patients referred at the right time, with fewer missed referrals and fewer unnecessary ones.
Where we're going
One platform, built in stages
Navicor is designed to grow with the clinical workflow — starting with a lightweight tool physicians can use today, and building toward deeper integration and patient-specific insight.
Navicor Early Access
An early version of our platform. Physicians input clinical findings and Navicor matches them to the relevant ACC/AHA guideline recommendations, with the reasoning and source shown for every match. It requires no patient-identifiable data and no integration, so practices can start using it immediately — and every early user helps shape what comes next.
Navicor with EHR Integration
We're actively building integration with electronic health record systems, so guideline matching happens inside the existing clinical workflow — working from information already in the record rather than manual entry.
NavicorMD
Our next-generation platform, extending Navicor with deeper, patient-specific clinical insight. NavicorMD is being developed as a regulated medical device and is not yet available. We look forward to sharing more as the program progresses.
Navicor supports, and does not replace, the clinical judgment of qualified healthcare professionals. Product availability and features are subject to change.
Momentum
Backed by Switzerland's innovation ecosystem
Augury Medical was founded in 2024 as a spin-off of the Bern University of Applied Sciences (BFH). Since then, we've been supported by leading Swiss innovation programs and investors.
Top 17, W.A. de Vigier Competition 2026
Selected among Switzerland's most promising startups.
Venture Leaders Medtech, Boston 2025
Selected for the Swiss national medtech team roadshow to the US.
Founded as a BFH spin-off
Built on applied cardiac research at BFH Technik & Informatik.
Supported & recognised by
We're raising our Seed round
We're raising Seed funding to bring Navicor to US primary care, complete EHR integration, and advance development of NavicorMD. We're looking for investors with experience in digital health and medical devices who share our conviction that clinical decisions should start with the patient — not the search bar.
If you'd like to learn more or request our investor materials, we'd be glad to hear from you.
Contact usThe information on this page is provided for general informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, any securities. Any such offer will be made only through definitive documentation provided to qualified investors.